Related Experiment Video
Updated: Jun 19, 2026
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
Published on: June 6, 2018
Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety
Alan Riley1, Mark Main, Frazer Morgan
1Kings Park Cwmann, Lampeter, Carmarthenshire, UK.
Introduction:
Erectile dysfunction (ED) treatment is greatly influenced by patient preference, and currently available oral therapies do not meet all patients' needs. New therapies and formulations are therefore being investigated.
Aim:
The aim of this article is to assess the clinical efficacy and safety of inhaled apomorphine, VR004, in men with mild to severe ED.
Main Outcome Measures:
Efficacy outcomes were the change in the proportion of positive responses to sexual encounter profile questions, International Index of Erectile Function (IIEF) scores and onset of therapeutic effect. Safety outcomes included a change in vital signs at an orthostatic challenge and adverse events (AEs).
Methods:
Two consecutive, multicenter trials each comprised a 4-week no-treatment period and a 12-week "at home" treatment period with regular clinic visits. Patients (N = 211 and N = 389) were randomized to receive one of three set doses of VR004 (100-300 microg) or matching placebo in each trial. VR004 was administered by a dry-powder inhaler at least once a week.
Results:
Efficacy was generally dose dependent. The proportion of per-protocol patients maintaining an erection long enough for successful intercourse increased in all VR004 groups vs. placebo. IIEF scores were higher in the VR004 groups compared with placebo, and the majority of responders achieved an erection within 10 minutes of dosing. The safety profile of VR004 was generally similar to that of placebo, and AEs were mild or moderate in severity. The incidence of treatment-related AEs was dose dependent. Few patients (4%) withdrew because of treatment-related AEs, and the majority of these withdrawals occurred on the day of the stringent orthostatic challenge.
Conclusions:
The VR004 system administers low apomorphine doses that are well tolerated without compromising efficacy. This route of administration ensures a rapid onset of action and reproducible efficacy and safety profiles. Inhaled apomorphine is therefore a potential first-line treatment for ED.
More Related Videos
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Related Concept Videos
01:23Inhaled Medications
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Drug Delivery: Enteral Route
Drugs in...
01:18Additional Routes of Drug Administration
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment